3.41 USD
-0.18 (-5.01%)
Taking everything into account, SNOA scores 3 out of 10 in our fundamental rating. SNOA was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of SNOA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SNOA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SNOA has reported negative net income.
SNOA had a negative operating cash flow in the past year.
In the past 5 years SNOA always reported negative net income.
In the past 5 years SNOA always reported negative operating cash flow.
1.2 Ratios
SNOA has a Return On Assets (-25.11%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -91.87%, SNOA is in line with its industry, outperforming 40.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.11% | ||
| ROE | -91.87% | ||
| ROIC | N/A |
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SNOA (37.68%) is comparable to the rest of the industry.
SNOA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SNOA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNOA has been increased compared to 1 year ago.
Compared to 5 years ago, SNOA has less shares outstanding
The debt/assets ratio for SNOA has been reduced compared to a year ago.
2.2 Solvency
SNOA has an Altman-Z score of -18.63. This is a bad value and indicates that SNOA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -18.63, SNOA is doing worse than 83.77% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that SNOA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.01, SNOA perfoms like the industry average, outperforming 56.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.63 |
ROIC/WACCN/A
WACC9.33%
2.3 Liquidity
A Current Ratio of 2.89 indicates that SNOA has no problem at all paying its short term obligations.
SNOA has a Current ratio of 2.89. This is comparable to the rest of the industry: SNOA outperforms 51.31% of its industry peers.
A Quick Ratio of 2.05 indicates that SNOA has no problem at all paying its short term obligations.
SNOA has a Quick ratio (2.05) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.05 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.30% over the past year.
SNOA shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.02%.
Measured over the past years, SNOA shows a decrease in Revenue. The Revenue has been decreasing by -4.44% on average per year.
EPS 1Y (TTM)55.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.76%
Revenue 1Y (TTM)25.02%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%56.58%
3.2 Future
Based on estimates for the next years, SNOA will show a very strong growth in Earnings Per Share. The EPS will grow by 28.15% on average per year.
The Revenue is expected to grow by 20.34% on average over the next years. This is a very strong growth
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3Y28.15%
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3Y20.34%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SNOA's earnings are expected to grow with 28.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.06%
EPS Next 3Y28.15%
5. Dividend
5.1 Amount
No dividends for SNOA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:SNOA (12/15/2025, 8:00:03 PM)
3.41
-0.18 (-5.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.49%
Inst Owner Change-38.77%
Ins Owners1.24%
Ins Owner Change0%
Market Cap5.80M
Revenue(TTM)16.94M
Net Income(TTM)-3.48M
Analysts85.71
Price Target15.1 (342.82%)
Short Float %1.24%
Short Ratio0.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.22%
Min EPS beat(2)-45.24%
Max EPS beat(2)-1.2%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)13.07%
Min Revenue beat(2)-2.81%
Max Revenue beat(2)28.95%
Revenue beat(4)1
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-17.11%
Max Revenue beat(4)28.95%
Revenue beat(8)1
Avg Revenue beat(8)-8.23%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.34 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.53 | ||
| P/tB | 1.53 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.2
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS9.96
BVpS2.23
TBVpS2.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.11% | ||
| ROE | -91.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.68% | ||
| FCFM | N/A |
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
F-Score4
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 121.32% | ||
| Cap/Sales | 0.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.05 | ||
| Altman-Z | -18.63 |
F-Score4
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)91.77%
Cap/Depr(5y)85.45%
Cap/Sales(3y)0.91%
Cap/Sales(5y)0.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.76%
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3Y28.15%
EPS Next 5YN/A
Revenue 1Y (TTM)25.02%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%56.58%
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3Y20.34%
Revenue Next 5YN/A
EBIT growth 1Y26.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.58%
OCF growth 3YN/A
OCF growth 5YN/A
SONOMA PHARMACEUTICALS INC / SNOA FAQ
What is the ChartMill fundamental rating of SONOMA PHARMACEUTICALS INC (SNOA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SNOA.
What is the valuation status for SNOA stock?
ChartMill assigns a valuation rating of 1 / 10 to SONOMA PHARMACEUTICALS INC (SNOA). This can be considered as Overvalued.
Can you provide the profitability details for SONOMA PHARMACEUTICALS INC?
SONOMA PHARMACEUTICALS INC (SNOA) has a profitability rating of 1 / 10.